Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUVN-911 PK and Safety Study (Food, Gender, and Age Effects)
NCT03551288Phase 1Completed
- Sponsor
- Suven Life Sciences
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ropanicant in major depressive disorder (MDD) (3 cohorts), sponsored by Suven Life Sciences. Primary endpoint: Area under concentration at 24 hours. Started May 2018; status: completed.
02
Drugs
Ropanicant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03551288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551288.